Detalhe da pesquisa
1.
Heberprot-P's Effect on Gene Expression in Healing Diabetic Foot Ulcers.
MEDICC Rev
; 20(3): 10-14, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31242156
2.
Uso profiláctico de nasalferon contra la COVID-19 en trabajadores de la salud. Estudio de vigilancia temprana / Prophylactic use of nasalferon against COVID-19 in healthcare workers. Early surveillance stud
Rev. habanera cienc. méd
; 21(2)abr. 2022.
Artigo
em Espanhol
| LILACS, CUMED | ID: biblio-1409465
3.
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
BMC Pharmacol Toxicol
; 17(1): 58, 2016 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27923408
4.
Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.
BMC Pharmacol Toxicol
; 14: 44, 2013 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24004460
5.
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.
Diabetes Care
; 36(2): 210-5, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22966096
6.
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
BMC Pharmacol Toxicol
; 13: 20, 2012 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23272809